

COMPANY OVERVIEW

Propanc is currently focused on developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ proenzymes, which are inactive precursors of enzymes.

RECENT NEWS

Propanc Biopharma Provides Shareholder Update

Jan 13 2026, 8:45 AM EST

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Dec 22 2025, 7:00 AM EST

Propanc Biopharma Investigates "Mesenchymal Drift" to Reverse Chronic Diseases Defined by Altos Labs

Dec 4 2025, 8:45 AM EST

STOCK OVERVIEW

Symbol	PPCB
Exchange	Nasdaq
Market Cap	5.79m
Last Price	\$0.4335
52-Week Range	\$0.4328 - \$145.46

01/13/2026 09:00 PM EST

INVESTOR RELATIONS

Propanc Biopharma, Inc.
T: +61-03-9882-6723
irteam@propanc.com

MANAGEMENT TEAM

James Nathanielsz

CEO and Executive Chairman

Dr. Julian Kenyon, M.D.

Chief Scientific Officer

Professor Klaus Kutz, M.D.

Chief Medical Officer

Jeannine Zimmerman

Chief Financial Officer

PROPANC BIOPHARMA, INC.

302/6 Butler Street
Camberwell, VIC 3124
AU

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.